IDEXX Laboratories Dirección
Dirección controles de criterios 4/4
El CEO de IDEXX Laboratories' es Jay Mazelsky , nombrado en Jun 2019, tiene una permanencia de 4.83 años. compensación anual total es $11.52M, compuesta por 8.7% salario y 91.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.098% de las acciones de la empresa, por valor de $40.24M. La antigüedad media del equipo directivo y de la junta directiva es de 4.5 años y 7.5 años, respectivamente.
Información clave
Jay Mazelsky
Chief Executive Officer (CEO)
US$11.5m
Compensación total
| Porcentaje del salario del CEO | 8.7% |
| Permanencia del CEO | 4.9yrs |
| Participación del CEO | 0.1% |
| Permanencia media de la dirección | 4.9yrs |
| Promedio de permanencia en la Junta Directiva | 7.6yrs |
Actualizaciones recientes de la dirección
Recent updates
IDEXX Laboratories, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
May 03
What IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) P/E Is Not Telling You
Apr 27IDEXX Laboratories (NASDAQ:IDXX) Has A Rock Solid Balance Sheet
Apr 11IDEXX: Strong Recurring Revenues From Consumables, Software But Overvalued (Rating Downgrade)
Apr 08Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jan 30IDEXX Laboratories: Valuation Rerating Doesn't Seem Justified
Jan 16Here's Why IDEXX Laboratories (NASDAQ:IDXX) Has Caught The Eye Of Investors
Jan 15IDEXX Laboratories, Inc.'s (NASDAQ:IDXX) Shareholders Might Be Looking For Exit
Dec 31IDEXX Laboratories (NASDAQ:IDXX) Seems To Use Debt Rather Sparingly
Dec 15Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Oct 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Is Well Worth Watching
Oct 10Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Sep 07Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jul 04These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
May 31At US$484, Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth Looking At Closely?
Apr 05Here's Why IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt Responsibly
Feb 22Why IDEXX Laboratories, Inc. (NASDAQ:IDXX) Could Be Worth Watching
Jan 05Is IDEXX Laboratories (NASDAQ:IDXX) Using Too Much Debt?
Nov 24When Should You Buy IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Sep 20IDEXX Laboratories: Outstanding Business, But Valuation Is Key
Aug 15These 4 Measures Indicate That IDEXX Laboratories (NASDAQ:IDXX) Is Using Debt Reasonably Well
Aug 15IDEXX Laboratories Stock Is Very Expensive
Aug 08IDEXX Laboratories Non-GAAP EPS of $1.58 misses by $0.05, revenue of $860.55M misses by $1.57M
Aug 02Are IDEXX Laboratories, Inc. (NASDAQ:IDXX) Investors Paying Above The Intrinsic Value?
Jul 26Here's Why We Think IDEXX Laboratories (NASDAQ:IDXX) Might Deserve Your Attention Today
Jul 12Is It Time To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Jun 16IDEXX Laboratories: Great Business, But Still Overvalued
May 25We Think IDEXX Laboratories (NASDAQ:IDXX) Can Manage Its Debt With Ease
May 06Is IDEXX Laboratories, Inc. (NASDAQ:IDXX) Worth US$474 Based On Its Intrinsic Value?
Apr 23With EPS Growth And More, IDEXX Laboratories (NASDAQ:IDXX) Is Interesting
Apr 09Is It Too Late To Consider Buying IDEXX Laboratories, Inc. (NASDAQ:IDXX)?
Mar 07IDEXX Laboratories And Its Real Value
Feb 02Does IDEXX Laboratories (NASDAQ:IDXX) Deserve A Spot On Your Watchlist?
Jan 06IDEXX: A Wonderful Business At An Unreasonably High Price
Nov 24Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | US$867m |
| Dec 31 2023 | US$12m | US$1m | US$845m |
| Sep 30 2023 | n/a | n/a | US$823m |
| Jun 30 2023 | n/a | n/a | US$791m |
| Mar 31 2023 | n/a | n/a | US$699m |
| Dec 31 2022 | US$10m | US$1m | US$679m |
| Sep 30 2022 | n/a | n/a | US$670m |
| Jun 30 2022 | n/a | n/a | US$664m |
| Mar 31 2022 | n/a | n/a | US$735m |
| Dec 31 2021 | US$9m | US$977k | US$745m |
| Sep 30 2021 | n/a | n/a | US$757m |
| Jun 30 2021 | n/a | n/a | US$728m |
| Mar 31 2021 | n/a | n/a | US$674m |
| Dec 31 2020 | US$7m | US$814k | US$582m |
| Sep 30 2020 | n/a | n/a | US$497m |
| Jun 30 2020 | n/a | n/a | US$460m |
| Mar 31 2020 | n/a | n/a | US$437m |
| Dec 31 2019 | US$7m | US$632k | US$428m |
| Sep 30 2019 | n/a | n/a | US$423m |
| Jun 30 2019 | n/a | n/a | US$407m |
| Mar 31 2019 | n/a | n/a | US$390m |
| Dec 31 2018 | US$3m | US$555k | US$377m |
| Sep 30 2018 | n/a | n/a | US$330m |
| Jun 30 2018 | n/a | n/a | US$307m |
| Mar 31 2018 | n/a | n/a | US$284m |
| Dec 31 2017 | US$2m | US$469k | US$263m |
Compensación vs. Mercado: La compensación total ($USD11.52M) de Jay está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD13.52M).
Compensación vs. Ingresos: La compensación de Jay ha sido consistente con los resultados de la empresa en el último año.
CEO
Jay Mazelsky (62 yo)
4.9yrs
Permanencia
US$11,519,309
Compensación
Mr. Jonathan J. Mazelsky, also known as Jay, serves as Independent Director at DENTSPLY SIRONA Inc. since May 24, 2023. He has been President, Chief Executive Officer and Director at IDEXX Laboratories, In...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.9yrs | US$11.52m | 0.098% $ 38.9m | |
| CFO, Executive VP & Treasurer | 10.3yrs | US$3.85m | 0.035% $ 14.0m | |
| Executive VP and GM of Reference Laboratories & Information Technology | 4.3yrs | US$2.92m | 0.0085% $ 3.4m | |
| Senior Vice President of Global Operations | 6.7yrs | sin datos | sin datos | |
| Senior Vice President of Commercial Finance & Sales Operations | 9.3yrs | sin datos | sin datos | |
| Executive VP & CTO | 2.8yrs | sin datos | sin datos | |
| Senior VP & Chief Information Officer | 8.3yrs | sin datos | sin datos | |
| Executive VP | no data | US$1.88m | 0.0067% $ 2.7m | |
| Executive VP & Chief Human Resources Officer | 2.2yrs | sin datos | 0.00022% $ 87.3k | |
| Senior VP & Chief Revenue Officer | no data | sin datos | 0.0083% $ 3.3m | |
| Senior VP and GM of Product & Strategy of Global Reference Labs | less than a year | sin datos | sin datos | |
| Executive VP and GM of Point of Care Diagnostics & Telemedicine | no data | sin datos | 0.013% $ 5.1m |
4.9yrs
Permanencia media
54yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de IDXX se considera experimentado (4.5 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 4.6yrs | US$11.52m | 0.098% $ 38.9m | |
| Independent Director | 11.8yrs | US$367.66k | 0.0076% $ 3.0m | |
| Independent Director | 10.2yrs | US$362.66k | 0.0031% $ 1.2m | |
| Independent Director | 8.8yrs | US$367.66k | 0.0023% $ 916.9k | |
| Non-Employee Director | 22.3yrs | US$335.16k | 0.70% $ 275.9m | |
| Independent Director | 6.8yrs | US$350.16k | 0.00068% $ 269.9k | |
| Independent Non-Executive Chairman | 7.6yrs | US$495.02k | 0.0091% $ 3.6m | |
| Independent Director | 10.8yrs | US$335.16k | 0.011% $ 4.2m | |
| Independent Director | less than a year | US$258.89k | 0% $ 0 | |
| Independent Director | 4.8yrs | US$342.66k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$335.16k | 0.00041% $ 162.7k |
7.6yrs
Permanencia media
61yo
Promedio de edad
Junta con experiencia: La junta directiva de IDXX se considera experimentada (7.5 años de antigüedad promedio).